Good morning, and welcome to Precipio's Quarterly Shareholder Update Conference Call. [Operator Instructions] I would now like to turn the conference over to [Mary Radomski], Precipio's in-house Counsel. Please go ahead.

Thank you. Good morning, all. Statements made during this call contain forward-looking statements about our business. You should not place undue reliance on forward-looking statements as these statements are based upon our current expectation forecast and assumptions and are subject to significant risks and uncertainties. These statements may be identified by words such as may; will; should; could; expect; intent; plan; anticipate; belief; estimate; predict; potential; forecast; continue or the negative of these terms or other words or terms similar meaning. Risks and uncertainties that could cause our actual results to differ materially from those set forth in the forward-looking statement include but are not limited to the matters listed under risks factors in our Quarterly Report on Form 10-Q for June 30, 2018, and our Annual Report on Form 10-K for the year ended December 31, 2017, which is on file with the Securities and Exchange Commission, as well as other risks detailed in our subsequent filings with the Securities and Exchange Commission. These reports are available at www.sec.com Statements and information including forward-looking statements speak only to the date they are provided unless an early date is indicated, and we do not undertake any obligations to publicly update any statement or information including forward-looking statements whether as result of new information, further events or otherwise, except as per required by law. Now, let me hand over the call to Ilan, Precipio's CEO.

Thank you, Mary. Good morning. I'd like to thank everyone for joining this call, and in particular, the many shareholders that submitted questions in advance. We'll do our best to answer those questions throughout our call today. I appreciate the attention, interest, and support of the Company's mission and after 14 months since the merger, I am more confident than ever in the value of our goal to relieve the untold suffering and wasted resources associated with disease misdiagnosis. Accelerating growth in the second quarter both in Pathology Services our Liquid Biopsy product development and other initiatives continue to demonstrate successful execution on our plan and our team's hard work and dedication in building the business. Following my update, Carl, our CFO, will share details of the Company's financial strategy, as well as provide an update on the quarter. As we've done previously, rather than the customary narrative of reciting the numbers recently filed in our 10-Q, we'd like to use this time to give you our perspective on where to extend and where the business is going. We hope you find this format more informative, and as always, we welcome your feedback by e-mail at investors@precipiodx.com. So with that, let me provide a business update on our progress and then Carl will provide a financial update, followed by few closing remarks from me. The [indiscernible] of our business continue to develop our Pathology Services and our Liquid Biopsy offering. On the Pathology Services side, we've doubled our sales team since the start of the year, from four to eight and this quarter we're adding four more talented reps to our team. Our experience has shown that the sales rep can reach breakeven within the first six months of his or her involvement, and by the end of the year…

Thank you, Ilan. Good morning. This is Carl Iberger, Chief Financial Officer. I’m glad to have this opportunity to provide additional insight regarding our company and our progress on 2018. Last week we filed our 10-Q. This filing and all of our quarterly filings are available to the public through our website or sec.gov/prpo. For today's call while I will focus on reported information, portions of my discussion will be related to ongoing business and therefore certain initiatives that may impact future events. During our Q1 shareholder call, I outlined five overarching financial initiatives necessary to grow our diagnostic business and to execute the business plan commercializing our genetic technology. Ilan has touched upon some of this and he will provide further discussion following my review. The key financial initiatives we have been pursuing are restructuring the balance sheet, capitalizing the company, managing expenses and driving initiatives to minimize our cash burn and leverage in place infrastructure both our hard assets and our human capital. And lastly creating financial opportunities looking at either make buy decisions or migrating internal functions to lower cost for applications. Our business today is growing. We see the trends in our in-path business and we are excited about the market opportunities and potential deployment of ICP technology. However today we are cash constrained, we are in a cash burn environment. Additional capital is necessary to fund the business and execute our business strategy. We’re actively pursuing financing and partnership arrangements which will allow the company to continue to move forward as we grow the diagnostic business and deploy ICP. Turning to our reported financials, we are encouraged by the reported results for Q1 and Q2. We have built momentum. On the revenue side for revenue growth, the steady continued growth in reported revenue in hemapath…

Thank you, Carl. Lastly I'd like to elaborate on a few points that were brought up by investors who sent in e-mails, regarding our liquidity situation and our plan to regain compliance with NASDAQ listing requirement to maintain a share price of above $1. Let's begin with our capital needs. We are a growing Company, and it's no secret we will require additional capital to fuel the growth of the exciting initiatives I described earlier on in the call. Every growth company faces the choice of organic growth, which is typically slower versus faster capital driven growth. If we can breakeven as quickly as possible with our goal, we could, for example, we have kept our sales team as it was at the start of the year rather than grow the team, and rely on organic growth as the sales force increases their business without any additional headcount and associated cost. We could have chosen not to invest in the development of marketing of ICE-COLD PCR and any one of the other technologies we've developed, and we could aim to reach breakeven much faster since the breakeven point would require less revenue. In the past as a Private Company, Precipio indeed reached breakeven at an approximate revenue run rate of $3 million. Theoretically the Company can reach a breakeven point and then slowly grow organically, reinvesting its own cash into gradual growth. However, I don't think that's what anyone signed up for. In our industry and at our stage, shareholder value is driven primarily by top line growth, which demonstrates market acceptance of the Company's offering against competition. Secondarily, by having a decent gross margin, which as Carl described, we have. And third, manageable overhead cost that don't soak up those margins. We have all those ingredients and I believe…

The conference is now concluded. Thank you for attending today's presentation. You may now disconnect.